Nitric Oxide-Releasing Drug

Phase 2Small molecule

SSanotize Research and Development corp.

Nitric Oxide-Releasing Drug is one of 95 small molecule programs targeting Sinusitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SinusitisActive, not recruiting

COVID-19Active, not recruiting

Diabetic FootActive, not recruiting

SinusitisPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Diabetic FootPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Nitric Oxide-Releasing Drug

SSanotize Research and Development corp.

Phase 2

1 3

Calciferol

Alnylam Pharmaceuticals

Tricor

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Calcium

Aprotinin

1 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Antithrombin-III

Octapharma

Preclinical

1 10

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection

Withdrawn·SSanotize Research and Development corp.·Phase 2·NCT04443868

Diabetic Foot1 trial

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers

Completed·SSanotize Research and Development corp.·Phase 1/2·NCT04755647·40 enrolled

Sinusitis1 trial

Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis

Active, not recruiting·SSanotize Research and Development corp.·Phase 2·NCT06264141·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nitric Oxide-Releasing Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nitric Oxide-Releasing Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nitric Oxide-Releasing Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanotize Research and Development corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSanotize Research and Development corp.

Nitric Oxide-Releasing Drug

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

Diabetic Foot1 trial

Sinusitis1 trial

References

Drug Info

Quick Facts

Related News